Clover Announces Positive Phase I Results for SCB-219M for Treatment of Chemotherapy-Induced Thrombocytopenia (CIT) (PRNewswire) - Dec 28, 2023 - P1 | N=76 | NCT05426369 | Sponsor: Sichuan Clover Biopharmaceuticals, Inc. | "Clover Biopharmaceuticals...announced positive preliminary safety, efficacy and pharmacokinetics data in a Phase I clinical trial evaluating SCB-219M, an innovative thrombopoietin receptor agonist (TPO-RA) mimetic bispecific Fc-fusion protein produced from CHO cells, for the treatment of cancer patients with chemotherapy-induced thrombocytopenia (CIT). All cancer patients enrolled to-date (n=9) receiving chemotherapy plus a single subcutaneous dose of SCB-219M observed platelet counts maintained or recovered at >75 x 109/L (threshold level for CIT) after one week, with responses durable through at least three weeks (i.e. through the chemotherapy cycle)....A Phase Ib trial evaluating repeated dosing of SCB-219M in CIT and CTIT patients is planned to initiate in 2024."
New P1 trial • P1 data • Thrombocytopenia
|